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ABSTRACT
Aims: To evaluate risk factors for major adverse cardiac event (MACE) after the first acute coron-
ary syndrome (ACS) and to examine the prevalence of risk factors in post-ACS patients.
Methods: We used Finnish population-based myocardial infarction register, FINAMI, data from
years 1993–2011 to identify survivors of first ACS (n¼ 12686), who were then followed up for
recurrent events and all-cause mortality for three years. Finnish FINRISK risk factor surveys were
used to determine the prevalence of risk factors (smoking, hyperlipidaemia, diabetes and blood
pressure) in post-ACS patients (n¼ 199).
Results: Of the first ACS survivors, 48.4% had MACE within three years of their primary event,
17.0% were fatal. Diabetes (p¼ 4.4 107), heart failure (HF) during the first ACS attack hospital-
ization (p¼ 6.8 1015), higher Charlson index (p¼ 1.56 1019) and older age (p¼ .026) were
associated with elevated risk for MACE in the three-year follow-up, and revascularization
(p¼ .0036) was associated with reduced risk. Risk factor analyses showed that 23% of ACS survi-
vors continued smoking and cholesterol levels were still high (>5mmol/l) in 24% although 86%
of the patients were taking lipid lowering medication.
Conclusion: Diabetes, higher Charlson index and HF are the most important risk factors of
MACE after the first ACS. Cardiovascular risk factor levels were still high among survivors of
first ACS.
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Cardiovascular diseases (CVD) are the leading cause of
death in many countries. In 2017 17.8 million people
died because of a CVD event [1]. Many studies have
been published on risk factors for coronary heart dis-
ease (CHD) which is the leading component of CVD
[1,2]. Age, male sex, hypertension, hyperlipidaemia,
diabetes and cigarette smoking are commonly consid-
ered as risk factors for CHD [3–6]. Also, left ventricular
systolic dysfunction, severity of CHD and comorbidities
are associated with high risk of an adverse out-
come [3,5,7].
Different risk indicators for major adverse cardiac
event (MACE) after an acute coronary syndrome (ACS),
such as angiographic outcome and left ventricular
function, have been previously observed [6,7]. Also,
the short-term risk of MACE after ACS is well known
[5,8,9]. However, the long-term risk factors for MACE
after an ACS have been rarely examined [5,8,10,11].
Previous studies have focussed on MACE after either a
non-ST-elevation myocardial infarction (NSTEMI) or ST-
elevation myocardial cinfarction (STEMI) and current
studies rarely separate between MACE after the first
event or recurrent event [5,7,11,12].
Major improvements have taken place in diagnosis
and treatment of ACS during past decades [13]. This
may have led to changes in most common risk factors
for MACE after ACS. The risk factors may be different
for first versus recurrent event and the risk factors for
long- and short-term recurrence may differ. Therefore,
it is important to evaluate the entire spectrum of
MACE after ACS in a long-term study.
The purpose of our study was to evaluate risk fac-
tors for MACE within one- and three-yeartime periods
after the first ACS event. In particular we wanted to
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identify modifiable risk factors, which could provide
treatment targets for further improvements in progno-
sis after the first ACS. We also examined the preva-
lence of risk factors (smoking, hyperlipidaemia,
diabetes and blood pressure) among a population-
based sample of post-ACS patients from the FINRISK
risk factor survey-populations to gain understanding
of the current treatment and control levels of these
risk factors.
Methods
This study was based on a follow-up of the FINAMI
participants. The FINAMI register has been described
previously [14]. In brief, it was a population- based
myocardial infarction register, which was functioning
in four different geographical areas of Finland. FINAMI
registered all events from Oulu, Joensuu, Turku and
Kuopio areas that were or were suspected to be myo-
cardial infarction (MI), unstable angina pectoris (UAP)
or CHD death [14]. Trained nurses collected the data
manually from hospital records [14]. FINAMI has
received approval from the Ethics Committee of the
National Institute for Health and Welfare during 21
January 2004.
Diagnostic classification of events was done accord-
ing to the American Heart Association (AHA) Scientific
Statement of 2003 [15] and before that according to
the WHO MONICA Project criteria [16]. The duration of
attack was defined as 28 days after onset of the attack.
The most severe symptoms and findings during this
time frame were recorded [14]. The attack was defined
as the first if there was no mention of previous symp-
tomatic events in the hospital records.
All symptomatic patients registered for their first
ACS in1993–2011 aged 35 to 74 years were included
in this study. Included patients did not have any previ-
ous symptomatic events according to the hospital
records and they had survived the first 28 days of their
first ACS event. MACE during the follow-up was identi-
fied by record linkage of the FINAMI data based on
the personal ID code with the National Hospital
Discharge Register (NHDR) and the Causes of Death
Register (CDR). Endpoints of the follow up (MACE)
were new fatal or non-fatal ACS (UAP or MI), fatal or
non-fatal heart failure (HF), fatal or non-fatal stroke,
fatal or non-fatal CVD event and all-cause death.
These events were identified from the NHDR and the
CDR using international classification of diseases (ICD)
9 and 10 (Finnish version) codes. Please see appendi-
ces for the specific codes.
We also examined a sample of FINRISK survey [17]
participants from survey years 2007 (n¼ 6258) and
2012 (N¼ 5827) to assess the prevalence of identified
cardiovascular risk factors amongst those participants
who had previously had ACS. FINRISK population has
been described in more detail in our previous article
[14]. In short, these patients were from the same geo-
graphic areas as the FINAMI patients and were aged
25–74 years. The same ICD 10 (Finnish version) codes
were used to identify patients with a history of ACS
event as for the FINAMI population.
Statistical methods
Examination of the data revealed that the proportional
hazards assumption was not fulfilled in time to event
models and therefore logistic regression was used to
calculate the odds ratios and confidence intervals for
risk factors of MACE. The models were adjusted for
age, sex (when relevant), study area and the year of
the event. Comparison of risk factors for MACE
between patients with different ACS event-types was
done using multivariate analysis which was adjusted
for age, study area and the year of event. Charlson
index [18] was used to evaluate the effect of comor-
bidity on mortality. It gives weighted points to
patients comorbidities [18]. History of MI, HF, periph-
eral vascular disease, cerebrovascular disease, para-
and hemiplegia, chronic obstructive lung disease,
rheumatoid disease, peptic ulcer disease, mild liver
disease and diabetes mellitus (DM) are weighed with
one point. DM with target organ damage, dementia,
renal disease and any cancer were weighted two
points. Moderate to severe liver disease was weighted
with three points and metastatic solid tumour and
AIDS (stage C) were weighted with six points [18]. For
the FINRISK population, the prevalence of current
smoking, high blood cholesterol level, use of lipid low-
ering drugs, diabetes and hypertension were estimated.
Results
Altogether, 12,686 patients survived 28 days after their
first ACS episode (Table 1). This was 61.9% of the total
first ever ACS patient population. Of these patients,
34.4% had MACE within one year and 48.4% within
three years of their primary event. Of these recurrent
MACE events, 17.6% were fatal within three years. We
also carried out a separate analysis, including only the
latest study years, 2006 2011. During this period,
altogether 3261 patients survived 28 days after their
first ACS episode. This was 62.3% of the total first ever
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ACS patient population. Of these patients, 36.2% had
MACE within one year and 48.4% within three years of
their primary event. Of these recurrent MACE events,
15.5% were fatal within three years. Among the whole
study population, the average age of having MACE
after the first ACS was 67.5 years for men and 76.9 for
women. The average time from ACS to MACE was less
than one year (0.77 years).
DM and HF within the first 28days of first ACS attack
and higher Charlson index were associated with higher
risk of MACE at one-year follow-up (Table 2). In the
three-year follow-up higher age and the same risk fac-
tors: DM, HF and Charlson index were associated with
higher risk of MACE. Only revascularization was a pro-
tective factor in both one- and the three-year follow-up.
Age, DM, and Charlson index were associated with
higher risk of stroke both in one- and three-year fol-
low-up (Table 3). Female sex and revascularization
were protective from stroke at one-year time point. At
three-year follow-up higher blood cholesterol was
inversely associated with stroke risk.
Table 4 shows risk factors for fatal MACE within
three years of index event (n¼ 2152). Older age, dia-
betes and primary HF increased the risk of fatal MACE
and protective factors were revascularization and later
year of the event.
The prevalence of risk factors among FINRISK partic-
ipants (from survey-years 2007 and 2012) who had a
history of their first ACS (N¼ 199) is shown in Table 5.
After the ACS event, 23% of patients were still smok-
ing. The number of patients currently taking lipid low-
ering drugs after ACS event was high (86%) but still
24% of them had total cholesterol 5mmol/l or more.
Discussion
The risk of recurrent MACE was high among survivors
of first ever ACS and a substantial proportion of these
Table 2. Risk factors for MACE after the first ACS event. All the risk factors were modelled independently of other risk factors
and adjusted for age, sex and event year.
MACE at one year (n¼ 4364) OR (CI / p Value) MACE at three years (n¼ 6094) OR (CI / p Value)
Age (per 10 years) 0.94 (0.88–1.01/.08) 1.07 (1.01–1.14/.026)
Sex (¼female) 0.88 (0.77–1.02/.095) 0.93 (0.81–1.06/.28)
Event year 0.99 (0.97–1.00/.13) 0.98 (0.97–1.00/.077)
Diabetes 1.39 (1.17–1.64/1.3 104) 1.51 (1.29–1.77/4.4 107)
Cholesterol (per SD) 1.00 (0.92–1.07/.93) 0.96 (0.9–1.03/.28)
Current smoking 1.12 (0.96–1.31/.14) 1.14 (0.98–1.31/.081)
Revascularization (within 28 days) 0.84 (0.73–0.97/.021) 0.82 (0.71–0.94/.0036)
Primary HF 1.95 (1.63–2.34/1.9 1013) 1.98 (1.67–2.36/6.8 1015)
Primary AF 1.1 (0.91–1.33 /.33) 1.11 (0.93–1.33/.25)
Use of thrombolytic treatment 1.12 (0.94–1.32/.2) 1.18 (1.01–1.38/.035)
Charlson index per 1 point 1.11 (1.09–1.13/1.94 1021) 1.09 (1.07–1.12/1.56 1019)
UAP (as AHADG, 15.4% of all cases) 0.99 (0.83–1.17/0.89) 1.11 (0.95–1.3/.18)
MACE: major adverse cardiac event; ACS: acute coronary event; OR: odds ratio; CI: confidence interval; SD: standard deviation; HF: heart failure; AF: atrial
fibrillation.Calculated in separate model, because the Charlson index includes primary HF and AF, adjusted for age and sex. The other ORs were produced in the
same model.
Table 1. Clinical characteristics of the study population.
Men Women Total
Survivors after first ACS (%) 6676 (62.8) 6010 (60.9) 12,686 (61.9)
Death within 1 year (%) 661 (9.9) 881 (14.7) 1542 (12.2)
Death within 3 years (%) 1369 (20.5) 1783 (29.7) 3152 (24.9)
MACE within 1 year (%) 2221 (33.3) 2143 (35.7) 4364 (34.4)
MACE within 3 years (%) 3019 (45.2) 3075 (51.2) 6094 (48.4)
Fatal MACE within 3 years (%) 852 (12.8) 1300 (21.6) 2152 (17.0)
Average age at MACE (SD) 67.5 (11.9) 76.9 (10.9) 72.0 (12.3)
Time from the first ACS to subsequent MACE in years (SD) 0.73 (0.76) 0.80 (0.78) 0.77 (0.77)
Stroke within 3 years (%) 448 (6.7) 522 (8.7) 970 (7.7)
ACS within 3 years (%) 2281 (34.2) 2092 (34.8) 4373 (34.5)
HF within first 28 days (%) 817 (12.2) 1231 (20.5) 2048 (16.4)
Prevalent DM among 28-day survivors (%) 729 (10.9) 872 (14.5) 1601 (12.6)
Current- / ex- / non-smokers among 28-day survivors (%) 1371 / 1290 / 721
(40.5 / 38.1 / 21.3)
480 / 314 / 1520
(20.7/ 13.6 / 65.7)
1851 / 1604 / 2241
(32.5 / 28.2 / 39.3)
Total cholesterol, mean (SD)







ACS: acute coronary syndrome; MACE: major adverse cardiac event; SD: standard deviation; MI: myocardial infarction; HF: heart failure; DM: dia-
betes mellitus.Percent of all first ACS cases. Percent of first MI survivors.
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events was fatal. Of first ever ACS patients 34.4% had
MACE within one year and 48.4% within three years of
their primary event. Previous studies have shown that
20.4% to 36.7% patients have MACE after ACS. The
proportion is lower for patient who have had revascu-
larization during the first attack [12,19]. DM and HF
during the first attack and high Charlson comorbidity
index were associated with a higher risk for MACE
within one- and three- years after the first ACS event.
Higher age was associated with higher risk in the
three-year follow-up. A revascularization procedure
was the only protective factor in both one- and three-
year time points. In FINRISK population, the risk factors
were still sub-optimally controlled amongst patients
who had survived one ACS event.
Not surprisingly, the higher Charlson comorbidity
index was associated with a higher risk for MACE and
stroke within one and three years after the first ACS
event in our study. It is likely that this is mainly due
to DM and HF being part of Charlson index. However,
other risk factors may also play a role since a previous
study by Radovanovic et al. [20] shows higher preva-
lence of elevated blood cholesterol, hypertension and
obesity in people with higher Charlson index.
Major improvements have taken place in the diag-
nosis and treatment of ACS during our study period
[13,14]. In our study population from the years
1993–2011, only one in four had angiographies during
the first attack. Revascularization became better avail-
able in Finland only after the year 2000 and has now
reached a plateau [21]. Even though the number of
patients who had angiography during first attack
period was relatively small in our study, revasculariza-
tion was still protective factor. This is in line with pre-
vious studies [5,19,22]. To explore the effects of
improved treatments, we carried out a separate ana-
lysis for the later study years, 2006–2011. The results
showed an improvement in both short- and long-term
survival, but among survivors the proportion of recur-
rent MACE events remained the same. Because of the
amount of revascularization procedures has reached a
plateau [21] it is fair to assume that if we aim to
improve long-term prognosis of ACS patients we
should also target the modifiable risk factor.
Most important modifiable risk factors for CVD
include hypertension, smoking, DM, obesity, physical
inactivity, unhealthy diet, high cholesterol and other
lipids and psychosocial factors [23–24]. In our study,
cholesterol was not a statistically significant risk factor
for MACE after ACS, which may be due to widespread
Table 3. Risk factors for stroke after the first ACS event. All the risk factors were modelled independently of other risk factors
and adjusted for age, sex and event year.
Stroke at one year (n¼ 545 (men¼ 250 and
women¼ 295)) OR (CI / p Value)
Stroke at three years (n¼ 970 (men¼ 448 and
women¼ 522)) OR (CI / p Value)
Age (per 10 years) 1.37 (1.14–1.65 / 9.3 104) 1.41 (1.23–1.63/ 1.4 106)
Sex (¼female) 0.66 (0.45–0.97/.033) 0.79 (0.59–1.05/.10)
Event year 1.00 (0.95–1.06/.85) 0.98 (0.94 1.01/.22)
Diabetes mellitus 1.84 (1.24–2.72/ .0022) 1.82 (1.35–2.43/ 6.6 105)
Cholesterol (per SD) 0.9 (0.73–1.1/.31) 0.82 (0.7–0.96/.014)
Current Smoking 0.96 (0.63-1.48/.87) 0.92 (0.67–1.28/.64)
Revascularization (within 28 days) 0.63 (0.42–0.93/ .021) 0.83 (0.62–1.12/.22)
Primary HF 0.69 (0.42–1.12/ .13) 0.8 (0.56-1.13/.21)
Primary AF 0.97 (0.6–1.57/.92) 0.98 (0.69-1.39/.9)
Use of thrombolytic treatment 0.82 (0.49-1.37 /.44) 1.06 (0.75-1.50 /.74)
Charlson index per 1 point 1.22 (1.10–1.36/ 2.9 104) 1.14 (1.05–1.25 / .0026)
UAP as index event (15.4% of all cases) 1.18 (0.76–1.84/.45) 0.95 (0.67–1.35 / .78)
ACS: acute coronary event; OR: odds ratio; CI: confidence interval; SD: standard deviation; HF: heart failure; AF: atrial fibrillation.Calculated in separate model, because the Charlson index includes primary HF and AF, adjusted for age and sex. The other ORs were produced in the
same model.
Table 4. Risk factors for fatal MACE (n¼ 2152) within three
years of index event.
OR CI p Value
Event Year 0.92 (0.9–0.95) 7.9e-8
Sex (female) 0.83 (0.68–1) .053
Age per 10 years 1.53 (1.39–1.7) 4.6e-17
Diabetes 2.38 (1.94–2.91) 7.3e-17
Cholesterol> 5 vs. 5 0.95 (0.86–1.05) .3
Current smoking 1.13 (0.9-1.42) .28
Revascularization (within 28 days) 0.56 (0.45–0.7) 1.5e-7
Primary HF 2.46 (1.99–3.02) 3e-17
Primary AF 1.02 (0.81–1.28) .89
UAP as index event (15.4% of all cases) 1.04 (0.82–1.32) .75
MACE: major adverse cardiac event; OR: odds ratio; CI: confidence inter-
val; HF: heart failure; AF: atrial fibrillation; UAP: unstable angina pectoris.
Table 5. Prevalence of known risk factors among FINRISK
2007 and 2012 survey participants with a history of first
ACS event.
Variable Men Women Total
N 158 (100%) 41 (100%) 199 (100%)
Smoking 34 (21%) 11 (27%) 45 (23%)
Cholesterol (>5mmol/l) 27 (17%) 21 (54%) 48 (24%)
Lipid lowering drug use 144 (91%) 27 (66%) 171 (86%)
Diabetes mellitus 57 (36%) 16 (39%) 73 (37%)
Hypertension (Bp >140/90 or
on medication)
114 (74%) 29 (74%) 143 (74%)
ACS: acute coronary syndrome; BP: blood pressure.
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use of statins after the first ACS event. In our FINRISK
population 86% of patients were taking lipid lowering
medication. However, 24% of the patients still had
total cholesterol 5mmol/l or more even with lipid low-
ering medication.
Smoking at the time of the first ACS tended to be
associated with elevated risk of future MACE but did
not reach statistical significance probably because
many patients stop smoking after the first ACS.
However, in our FINRISK sample 23% of patients were
still smoking after their first ACS. The FINRISK popula-
tion showed suboptimal secondary prevention after
the first ACS. Our sample size of post-ACS patients is
smallish, but the findings are consistent with the
EUROASPIRE study [25].
A previous study by our group [26] showed that
regular use of secondary preventive medications low-
ers the risk of recurrent ACS after the primary attack
and that the use of medications was suboptimal in
the elderly and in patients with diabetes. In our pre-
sent study the elderly and patients with DM were
both at higher risk of MACE after ACS and the sub-
optimal use of medication, and thus suboptimal sec-
ondary prevention, could in part explain the high
MACE rate for these patients. The specific medication
data was not available for our study and we did not
have the blood pressure values either.
The strength of our study is the FINAMI register
which was a large, population-based register covering
all ACS cases in monitored populations. FINAMI data
enabled us to identify and analyse all first ACS events
in populations of the register areas, and the record
linkage of FINAMI data to the NHDR and the CDR
through the personal ID number made it possible to
identify patients who had MACE after the first ACS
event. This ensured complete identification of the
MACE patients who were hospitalized or who died
either in hospital or out of hospital.
In addition to the previously mentioned limitations,
FINAMI does not separate NSTEMI from STEMI.
Therefore, we could not consider different types of MI.
While NHDR diagnosis for MI has shown to be valid
[27] this is not the case for the NSTEMI and STEMI
diagnoses [28].
In conclusion, DM and HF are the most important
risk factors for MACE after ACS. Revascularization was
clearly protective factor. Also, the treatment of risk fac-
tors seems to be at suboptimal level among the survi-
vors of first ACS. Based on our findings in FINRISK
population, especially hypercholesterolaemia should
be treated more aggressively and patients should be
actively encouraged to stop smoking. This highlights
the importance of secondary prevention for ACS
patients and also the significance of up-to-date scien-
tific research on risk factors and their changes in
populations.
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APPENDIX
ICD codes
International Classification of Diseases (ICD) codes were
used to cross-check the FINAMI data with the National
Hospital Discharge Register (NHDR) and the Causes of Death
Register (CDR). ICD 9 (Finnish version) was used until the end
of 1995 and ICD 10 (Finnish version) after that. Out of hos-
pital deaths were evaluated if the underlying or direct cause
of death was coronary heart disease (ICD 9: 410–414, ICD 10:
I20–I25) or cardiac arrest (I46.1, I46.9). Sudden death was also
considered for registration if the cause was unknown or
unattended death (ICD 9: 798, ICD 10: R96, R98). The National
Hospital Discharge register was cross-checked for hospitalisa-
tion due to MI or UAP (ICD 9: 410–411, ICD 10: I20–22). The
local registration teams evaluated these cases according to
the registration protocol [1,2]. NHDR and CDR have been vali-
dated earlier [3]. Stroke was identified using ICD 9 codes 431,
4330A, 4331A, 4339A, 4340A, 4341A, 4349A and 436, and
ICD 10 codes I61, I63 and I64 (except I63.6 was excluded)
from the NHDR and the CDR. Heart failure was identified
using ICD 9 codes 428and 4289X, and ICD 10 codes I50 and
I50.0 from the NHDR and CDR.
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